文献速递泌尿生殖介入MR

前列腺MR机架内引导活检中增量穿刺芯数与第二病灶取样的诊断价值

Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
PubMed 文献 · AJR Am J Roentgenol · 2020-12-18

该回顾性研究纳入128例男性共163个前列腺病灶,评估机架内MRI引导活检中从原发病灶获取递增穿刺芯数及第二病灶取样的诊断价值。结果显示第2芯任何升级频率12.9%、升级为临床显著前列腺癌(csPCa)7.4%;第4芯及第二病灶取样升级率极低。结论认为获取3芯可优化csPCa诊断,第4芯或第二病灶取样价值很低。

要点

  • 第2芯任何升级频率12.9%(21/163),升级为csPCa频率7.4%(12/163)。
  • 第4芯任何升级仅1.9%(1/52),升级为csPCa为0%(0/52)。
  • 第二病灶取样仅1例(2.5%,1/40)出现升级,该例两个病灶均为PI-RADS 4类且均显示csPCa。

核心结论

  • 进行前列腺机架内MRGB时,从原发病灶获取3芯可优化csPCa诊断;获取第4芯或对第二病灶取样在升级癌症诊断方面价值很低。

研究设计与样本

  • 回顾性研究纳入128例男性共163个前列腺病灶,于2016年至2019年间接受机架内MRGB。

关键影像表现/征象

  • 163个病灶取样2芯或以上,121个病灶取样3芯或以上,52个病灶取样4芯或以上。
  • 40例男性接受了第二病灶取样。

诊断标准与关键数值

  • 给定穿刺芯的升级定义为相对于之前获取的穿刺芯,国际泌尿病理学会(ISUP)分级分组(GG)更高。
  • 临床显著前列腺癌(csPCa)定义为ISUP GG 2或以上。

临床应用与阅片要点

  • 作者认为,为优化csPCa诊断,进行机架内MRGB时从原发病灶获取3芯是有依据的。
  • 作者指出,获取第4芯或对第二病灶取样在升级癌症诊断方面价值很低。
  • 为减少患者不适和手术时间,操作者可能避免获取超过3芯或进行第二病灶取样。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. In-gantry MRI-guided biopsy (MRGB) of the prostate has been shown to be more accurate than other targeted prostate biopsy methods. However, the optimal number of cores to obtain during in-gantry MRGB remains undetermined. OBJECTIVE. The purpose of this study was to assess the diagnostic yield of obtaining an incremental number of cores from the primary lesion and of second lesion sampling during in-gantry MRGB of the prostate. METHODS. This retrospective study included 128 men with 163 prostate lesions who underwent in-gantry MRGB between 2016 and 2019. The men had a total of 163 lesions sampled with two or more cores, 121 lesions sampled with three or more cores, and 52 lesions sampled with four or more cores. A total of 40 men underwent sampling of a second lesion. Upgrade on a given core was defined as a greater International Society of Urological Pathology (ISUP) grade group (GG) relative to the previously obtained cores. Clinically significant prostate cancer (csPCa) was defined as ISUP GG 2 or greater. RESULTS. The frequency of any upgrade was 12.9% (21/163) on core 2 versus 10.7% (13/121) on core 3 (p = .29 relative to core 2) and 1.9% (1/52) on core 4 (p = .03 relative to core 3). The frequency of upgrade to csPCa was 7.4% (12/163) on core 2 versus 4.1% (5/121) on core 3 (p = .13 relative to core 2) and 0% (0/52) on core 4 (p = .07 relative to core 3). The frequency of upgrade on core 2 was higher for anterior lesions (p < .001) and lesions with a higher PI-RADS score (p = .007); the frequency of upgrade on core 3 was higher for apical lesions (p = .01) and lesions with a higher PI-RADS score (p = .01). Sampling of a second lesion resulted in an upgrade in a single patient (2.5%; 1/40); both lesions were PI-RADS category 4 and showed csPCa. CONCLUSION. When performing in-gantry MRGB of the prostate, obtaining three cores from the primary lesion is warranted to optimize csPCa diagnosis. Obtaining a fourth core from the primary lesion or sampling a second lesion has very low yield in upgrading cancer diagnoses. CLINICAL IMPACT. To reduce patient discomfort and procedure times, operators may refrain from obtaining more than three cores or second lesion sampling.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Seyfried N, Mahran A, Panda A, et al. Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy. AJR Am J Roentgenol. 2020. PMID: 33336582. doi:10.2214/AJR.20.24918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。